Description: BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions comprising glaucoma, dry eye syndrome, and age-related macular degeneration. The company's ophthalmic product offering and pipeline of product candidates include IOPtiMate, a laser-based surgical treatment for glaucoma; TeaRx, a point-of-care multi-parameter diagnostic test for dry eye syndrome; Eye-D, a controlled release drug-delivery insert platform; OphRx, a non-invasive topical drug delivery technology; and LipiTear, a micro-emulsion technology for the dry eye treatment, as well as for the treatment of other ocular diseases. It also invests in cancer diagnostics technologies, including proprietary tests that are designated for bladder, cervical, multiple myeloma, and other cancers. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was founded in 2005 and is based in Tel Aviv, Israel.
Home Page: bio-light.co.il
Atidim Park Tel Aviv
Tel Aviv,
6158101
Israel
Phone:
972 7 327 53400
Officers
| Name | Title |
|---|---|
| Mr. Yaacov Michlin | Chief Exec. Officer |
| Mr. Yifftach Biel CPA | Chief Financial Officer |
| Ms. Karin Gurevitz | VP, Group Gen. Counsel, Chief Compliance Officer & Company Sec. |
| Ms. Ronit Gross | Co-Founder |
| Dr. Ron Neumann M.D. | Chief Medical Officer & Member of Scientific Advisory Board |
Exchange: TA
Country: IL : Israel
Currency: Israeli Agora (ILA)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 98.75 |
| Price-to-Book MRQ: | 0.6128 |
| Price-to-Sales TTM: | 4936.7114 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |